NV-WESTERN-UNION-COMPANY
Reflecting its strategic focus in digital expansion, The Western Union Company (NYSE: WU) today outlined specific enhancements to its services for its consumer-to-consumer (C2C) and business-to-business (B2B) customers.
A new omni-channel feature on the Western Union mobile app gives consumers the flexibility to send money to more than 200 countries and territories using multiple payment options. They can use the in-app payment choice of bank account, card or now use cash via an agent location. This new feature is available in the US and the UK and is planned to be rolled out globally over the coming year.
The company also announced an expansion of its payment platform for businesses that enables large enterprises to send high volumes of cross-currency and cross-border payments simultaneously.
“Consumers and businesses demand freedom of choice in today’s world,” said Western Union President and CEO Hikmet Ersek. “Western Union makes the lives of our customers easier and less complex – whether someone wants to send money from their phone that can be picked up in person, or helping businesses of all sizes grow.”
Western Union C2C Omni-Channel Mobile App
Western Union has expanded its digital footprint significantly, and consumers can now send money globally via WU.com in 37 countries or Western Union mobile app in 16 countries. The omni-channel enhancement provides additional convenience of starting the transaction on their smart phone, even if paying with cash, which significantly speeds up the in-store transaction. The company expects to roll out the service in the coming months in France, Germany, and Canada.
“Omni-channel choice is a thoughtful innovation which brings the advantages of digital transactions into a physical world,” said Western Union President of the Americas and European Union Odilon Almeida. “Our large, fast-growing digital network, combined with our regulatory understanding and compliance infrastructure, gives us opportunities to drive real value in all money transfer scenarios.”
Western Union Business Mass Payments
Corporate and Financial Institutions can now conveniently and efficiently send high volumes of payments across a multitude of countries and currencies. The enhanced Mass Pay offering builds on the core payments platform that underpins the company’s proprietary award-winning WU® EDGE™ platform, leveraging Western Union’s unique global banking network to drive speed and efficiency in making global payments.
“Our enhanced Mass Payments product offers unprecedented ease whereby Corporate and Financial Institutional customers can implement an international Mass Payments solution for their business. With an enriched suite of integration options, including a direct application programming interface (API) as well as SWIFT FIN connections, our customers can be up and running with our new service in days. This release reinforces our unique capabilities that have led us to become one of the largest non-bank providers of international payments in the world,” said Western Union Business Solutions President Kerry Agiasotis.
About Western Union
The Western Union Company (NYSE: WU) is a leader in global payment services. Together with its Vigo, Orlandi Valuta, Pago Facil and Western Union Business Solutions branded payment services, Western Union provides consumers and businesses with fast, reliable and convenient ways to send and receive money around the world, to send payments and to purchase money orders. As of June 30, 2016, the Western Union, Vigo and Orlandi Valuta branded services were offered through a combined network of over 500,000 agent locations in 200 countries and territories and over 100,000 ATMs and kiosks, and included the capability to send money to billions of accounts. In 2015, The Western Union Company completed 262 million consumer-to-consumer transactions worldwide, moving $82 billion of principal between consumers, and 508 million business payments. For more information, visit www.westernunion.com .
WU-G
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005485/en/
Contact:
Western Union Corporate Communications
GLOBAL
Dan
Diaz,
+1 303-547-2347
dan.diaz@westernunion.com
or
AMERICAS
& EUROPE
Pia De Lima,
+1 944-260-5732
pia.delima@westernunion.com
or
WUBS
Liesl
Smith,
+44 (0) 7710 185864
liesl.smith@westernunion.com
or
Fleishman
Hillard
Leslie Park,
+1 212-453-2111
leslie.park@fleishman.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom